SchrodingerSDGR
SDGR
About: Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Employees: 787
0
Funds holding %
of 7,245 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
206% more call options, than puts
Call options by funds: $15.3M | Put options by funds: $5M
33% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 24
15% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 65
10% more capital invested
Capital invested by funds: $1.19B [Q4 2024] → $1.31B (+$117M) [Q1 2025]
6.61% more ownership
Funds ownership: 97.19% [Q4 2024] → 103.8% (+6.61%) [Q1 2025]
2% more funds holding
Funds holding: 210 [Q4 2024] → 214 (+4) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$32
56%
upside
Avg. target
$39
88%
upside
High target
$45
119%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Keybanc Scott Schoenhaus | 56%upside $32 | Overweight Maintained | 16 Apr 2025 |
Piper Sandler Joseph Catanzaro | 119%upside $45 | Overweight Maintained | 27 Feb 2025 |
Financial journalist opinion
Based on 10 articles about SDGR published over the past 30 days
Neutral
Accesswire
18 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. ("Schrödinger" or the "Company") (NASDAQ:SDGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Positive
Seeking Alpha
1 day ago
Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)
Schrödinger delivered strong Q1 results, with robust software growth and improving margins, despite a tough macro environment. Regulatory changes, especially the FDA's move away from animal testing, could create a meaningful tailwind for Schrödinger's predictive toxicity software initiative. Schrödinger's Drug Discovery business also continues to progress, but this likely won't matter until the company generates positive later stage clinical data.
Neutral
Business Wire
2 days ago
Schrödinger Announces CFO Appointment
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced that the company and Geoffrey Porges, MBBS., have mutually agreed that Dr. Porges will depart from his role as chief financial officer to pursue other opportunities. Richie Jain, who previously served as Schrödinger's senior vice president, strategic finance and head of corporate and business development, will succeed Geoffrey Porges as chief financial officer. Dr. Porges will serve as an advisor to the company through June 6.
Neutral
Business Wire
1 week ago
Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, taking place June 17 - 21, 2025, in Lugano, Switzerland. The Phase 1 study is designed to evaluate the safet.
Negative
Zacks Investment Research
2 weeks ago
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.76 per share a year ago.
Neutral
Seeking Alpha
2 weeks ago
Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Affairs Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President, R&D & Therapeutics Conference Call Participants Michael Yee - Jefferies Brendan Smith - TD Cowen Mani Foroohar - Leerink Partners Evan Seigerman - BMO Capital Markets Michael Ryskin - Bank of America Scott Schoenhaus - KeyBanc Vikram Purohit - Morgan Stanley Operator Thank you for standing by. Welcome to Schrödinger's conference call to review First Quarter 2025 Financial Results.
Neutral
Business Wire
2 weeks ago
Schrödinger Reports Strong First Quarter 2025 Financial Results
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced financial results for the quarter ended March 31, 2025.
Neutral
Business Wire
2 weeks ago
Schrödinger to Present at BofA Securities 2025 Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference. The live presentation will take place on Wednesday, May 14, 2025 at 4:40 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computatio.
Neutral
Business Wire
3 weeks ago
Schrödinger Presents New Preclinical Data at AACR Annual Meeting
CHICAGO--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research (AACR) Annual Meeting 2025. The data demonstrated that SGR-3515 has improved anti-tumor activity in preclinical models compared to known Wee1 and Myt1 monotherapy inhibitors. The poster also described how the dosing schedule of SGR-3515 can be optimized to preserve efficacy and minimize target-related.
Neutral
Business Wire
4 weeks ago
Schrödinger to Announce First Quarter 2025 Financial Results on May 7
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close.
Charts implemented using Lightweight Charts™